Your browser doesn't support javascript.
loading
Reirradiation salvage radiotherapy for recurrent prostate cancer after primary low-dose brachytherapy.
Muñoz Muñoz, Óscar; Gomis Sellés, Elías; Delgado León, Blas David; Mateos Perez, Juan Carlos; Baeza Trujillo, Montserrat; Perucha Ortega, Maria; López Guerra, José Luis; Cabrera Roldán, Patricia.
Afiliação
  • Muñoz Muñoz Ó; Department of Radiation Oncology, University Hospital Virgen del Rocío, Manuel Siurot Avenue, S/N., 41013, Seville, Spain.
  • Gomis Sellés E; Department of Radiation Oncology, University Hospital Virgen del Rocío, Manuel Siurot Avenue, S/N., 41013, Seville, Spain.
  • Delgado León BD; Department of Radiation Oncology, University Hospital Virgen del Rocío, Manuel Siurot Avenue, S/N., 41013, Seville, Spain.
  • Mateos Perez JC; Department of Medical Physiology and Biophysics, Medical Radiation Physics, University of Seville, University Hospital Virgen del Rocío, Seville, Spain.
  • Baeza Trujillo M; Department of Medical Radiation Physics, University Hospital Virgen del Rocío, Seville, Spain.
  • Perucha Ortega M; Department of Medical Radiation Physics, University Hospital Virgen del Rocío, Seville, Spain.
  • López Guerra JL; Department of Radiation Oncology, University Hospital Virgen del Rocío, Manuel Siurot Avenue, S/N., 41013, Seville, Spain. chanodetriana@yahoo.es.
  • Cabrera Roldán P; Department of Radiation Oncology, University Hospital Virgen del Rocío, Manuel Siurot Avenue, S/N., 41013, Seville, Spain.
Clin Transl Oncol ; 26(4): 872-879, 2024 Apr.
Article em En | MEDLINE | ID: mdl-37672205
PURPOSE: Local recurrence of prostate cancer after low-dose rate brachytherapy is a clinical problem with limited salvage treatment options. This prospective study evaluated the tolerability and outcome of salvage external beam radiation therapy (S-EBRT) for locally recurrent prostate cancer after primary low-dose rate prostate brachytherapy (LDR-BT). MATERIALS AND METHODS: Between October 2012 and 2022, 18 patients with biopsy-proven locally recurrent prostate cancer after primary LDR-BT and received S-EBRT. We evaluated biochemical failure (BF), overall survival (OS) and acute/late gastrointestinal and urinary toxicities (CTCAE v5.0 or CTCAE v4, only before 2017). RESULTS: Median follow-up was 32 months (range, 5-124). The median age was at S-EBRT 68 years (range 59-79). 34% (6/18) were low risk, 44% (8/18) intermediate risk, 5% (1/18) high risk, and 17% (3/18) not specified. All patients were treated with IMRT/VMAT and received 60 Gy (2.5 Gy/fraction) to the prostate and 40% (7/18) 55.2 Gy (2,3 Gy/fx) to the seminal vesicles. 56% received ADT The 3-year OS and biochemical relapse-free survival after S-EBRT were 100% and 89%, respectively, with a median PSA nadir 0,035 ng/mL (0,01-0,34). Acute cystitis was present in 72% (13/18) of patients (27% of Grade > 2). Urethritis was present in 78% (14/18) patients (16% of cases Grade > 3), and acute rectitis occurred in 22% (4/18) of patients (no cases Grade > 3). CONCLUSIONS: Our data suggest that the treatment of locally recurrent prostate cancer with S-EBRT could provide adequate disease control safely and be used as an additional treatment in the natural history of prostate cancer patients. However, the results are still early and the sample is small; larger studies with longer follow-up would be mandatory.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Braquiterapia / Reirradiação Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha País de publicação: Itália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Braquiterapia / Reirradiação Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha País de publicação: Itália